An open-label extension study of lurasidone in patients with schizophrenia previously randomized to lurasidone or risperidone

被引：0
|
作者：
Mattingly, G. [1 ]
Tocco, M. [2 ]
Cucchiaro, J. [3 ]
Xu, J. [3 ]
Pikalov, A. [3 ]
Loebel, A. [3 ]
机构：
[1] St Charles Psychiat Associates, St Charles, MO USA
[2] Sunov Pharmaceut Inc, Marlborough, MA USA
[3] Sunov Pharmaceut Inc, Ft Lee, VA USA
来源：
EUROPEAN NEUROPSYCHOPHARMACOLOGY | 2014年 / 24卷
关键词：
D O I：
10.1016/S0924-977X(14)70895-8
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P.3.d.062
引用
收藏
页码：S559 / S559
页数：1
相关论文
共 50 条
  • [21] Effectiveness of lurasidone in schizophrenia or schizoaffective patients switched from other antipsychotics: a 6-month, open-label, extension study
    Citrome, Leslie
    Weiden, Peter J.
    McEvoy, Joseph P.
    Correll, Christoph U.
    Cucchiaro, Josephine
    Hsu, Jay
    Loebel, Antony
    CNS SPECTRUMS, 2014, 19 (04) : 330 - 339
  • [22] EFFICACY AND SAFETY OF LURASIDONE IN ADOLESCENTS WITH SCHIZOPHRENIA: INTERIM ANALYSIS OF A 24-MONTH, OPEN-LABEL EXTENSION STUDY
    Goldman, Robert
    Tocco, Michael
    Pikalov, Andrei
    Cucchiaro, Josephine
    Deng, Ling
    Loebel, Antony
    SCHIZOPHRENIA BULLETIN, 2018, 44 : S239 - S239
  • [23] Long-term safety and effectiveness of lurasidone in schizophrenia: a 22-month, open-label extension study
    Correll, Christoph U.
    Cucchiaro, Josephine
    Silva, Robert
    Hsu, Jay
    Pikalov, Andrei
    Loebel, Antony
    CNS SPECTRUMS, 2016, 21 (05) : 393 - 402
  • [24] LONG-TERM SAFETY AND EFFECTIVENESS OF LURASIDONE IN SCHIZOPHRENIA: RESULTS OF A 22 MONTH, OPEN-LABEL EXTENSION STUDY
    Pikalov, Andrei
    Correll, Christoph
    Cucchiaro, Josephine
    Silva, Robert
    Hsu, Jay
    Loebel, Antony
    SCHIZOPHRENIA RESEARCH, 2014, 153 : S178 - S178
  • [25] Clinical Efficacy and Safety Profile of Lurasidone Comparing with Risperidone: Randomized, Open Label, Clinical Study
    Sreedhar, V
    Reddenna, L.
    Rajavardhana, T.
    Rudra, J. Thippe
    Kumar, E. Pavan
    Kumar, M. Pramod
    Sai, M. Kalyan
    Sivasaileela, T.
    Yamini, Y.
    Sreelekha, B.
    Nishkala, B.
    Mahesh, M.
    JOURNAL OF PHARMACEUTICAL RESEARCH INTERNATIONAL, 2021, 33 (04) : 20 - 27
  • [26] Effectiveness of Lurasidone in Patients With Schizophrenia or Schizoaffective Disorder Switched From Other Antipsychotics: A Randomized, 6-Week, Open-Label Study
    McEvoy, Joseph P.
    Citrome, Leslie
    Hernandez, David
    Cucchiaro, Josephine
    Hsu, Jay
    Pikalov, Andrei
    Loebel, Antony
    JOURNAL OF CLINICAL PSYCHIATRY, 2013, 74 (02) : 170 - 179
  • [27] SAFETY AND EFFICACY OF DIFFERENT INITIAL DOSES OF LURASIDONE IN THE SCHIZOPHRENIA TREATMENT: A RANDOMIZED, OPEN-LABEL, MULTI- CENTER STUDY
    Liu, Qi
    Wu, Qi
    Yu, Xin
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2025, 28 : I158 - I158
  • [28] Safety and effectiveness of lurasidone in adolescents with schizophrenia: results of a 2-year, open-label extension study (pg 1, 2020)
    Correll, Christoph U.
    Findling, Robert L.
    Tocco, Michael
    Pikalov, Andrei
    Deng, Ling
    Goldman, Robert
    CNS SPECTRUMS, 2022, 27 (01) : 129 - 129
  • [29] EFFICACY AND SAFETY OF LURASIDONE IN ADOLESCENTS WITH SCHIZOPHRENIA: INTERIM ANALYSIS AT TWELVE MONTHS OF A 24-MONTH, OPEN-LABEL EXTENSION STUDY
    Correll, Christoph
    Tocco, Michael
    Goldman, Robert
    Pikalov, Andrei A.
    Cucchiaro, Josephine
    Loebel, Antony
    JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 2017, 56 (10): : S245 - S245
  • [30] Switching to Lurasidone following 12 months of treatment with Risperidone: results of a 6-month, open-label study
    Greg W. Mattingly
    Peter M. Haddad
    Michael Tocco
    Jane Xu
    Debra Phillips
    Andrei Pikalov
    Antony Loebel
    BMC Psychiatry, 20
12345